<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(2)</volume><submitter>Cao Y</submitter><funding>Telix Pharmaceuticals</funding><funding>National Cancer Institute</funding><journal>Pharmaceutics</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12944229</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma</pubmed_title><pmcid>PMC12944229</pmcid><funding_grant_id>K08CA249047</funding_grant_id><funding_grant_id>K08CA259626</funding_grant_id><pubmed_authors>Salari K</pubmed_authors><pubmed_authors>Esfahani S</pubmed_authors><pubmed_authors>Talluto J</pubmed_authors><pubmed_authors>Blute M</pubmed_authors><pubmed_authors>Dahl D</pubmed_authors><pubmed_authors>Heidari P</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>McVeigh T</pubmed_authors><pubmed_authors>Kim J</pubmed_authors></additional><is_claimable>false</is_claimable><name>89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma</name><description/><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-11T03:16:51.444Z</modification><creation>2026-07-11T03:12:00.714Z</creation></dates><accession>S-EPMC12944229</accession><cross_references/></HashMap>